Department of Chemical Sciences and Technologies, University of "Tor Vergata", Rome, Italy.
Arch Biochem Biophys. 2010 Aug 15;500(2):116-22. doi: 10.1016/j.abb.2010.05.012. Epub 2010 May 28.
Chemoresistance is a multifactorial phenomenon and many studies clearly show that a coordinated expression of efflux transporter proteins and phase II conjugating enzymes in tumor cells is linked to the development of the multidrug resistance phenotype. In particular, the overexpression of glutathione S-transferases and efflux pumps in tumors may reduce the reactivity of various anticancer drugs. In recent years it has become evident that glutathione S-transferases are also involved in the control of apoptosis through the inhibition of the JNK signaling pathway. As such, the glutathione S-transferase superfamily has become the focus of extensive pharmaceutical research in attempt to generate more efficient anticancer agents. Here we present an overview of the GST inhibitors and the GST-activated pro-drugs utilized to date to overcome drug resistance.
耐药性是一种多因素现象,许多研究清楚地表明,肿瘤细胞中流出转运蛋白和相 II 结合酶的协调表达与多药耐药表型的发展有关。特别是,谷胱甘肽 S-转移酶和流出泵在肿瘤中的过度表达可能会降低各种抗癌药物的反应性。近年来,谷胱甘肽 S-转移酶通过抑制 JNK 信号通路参与细胞凋亡的控制已变得明显。因此,谷胱甘肽 S-转移酶超家族已成为广泛药物研究的重点,试图开发更有效的抗癌药物。在这里,我们概述了迄今为止用于克服耐药性的 GST 抑制剂和 GST 激活的前药。